CD93 and nasopharyngeal carcinoma: Moreover, silencing CD93 in the NPC cell line CNE2 significantly reduced cell proliferation, demonstrating the key role of CD93 in NPC progression and angiogenesis, and validating this protein as a novel therapeutic target in NPC [13].